Aspire Biopharma Holdings (ASBP) Gross Margin (2025 - 2026)

Aspire Biopharma Holdings' (ASBP) quarterly Gross Margin came in at 20.28% in Q1 2026, up 186.41% on a QoQ basis from 23.47% in Q4 2025.

Aspire Biopharma Holdings (ASBP) Gross Margin (2025 - 2026) Analysis & Trends

Aspire Biopharma Holdings (ASBP) has 2 years of Gross Margin data on file, last reported at 20.28% in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Gross Margin (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn	88.95%
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn	86.85%
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn	91.79%
7	Belite Bio	62.72 Bn	62.72 Bn	-	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn	90.68%
9	Revolution Medicines	37.35 Bn	37.35 Bn	-	-
10	Aspire Biopharma Holdings	1.09 Mn	-733,865.14	5,750.00	20.28%

Download Data